Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Dermatology Product Name: AVT02

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2021

            Details:

            AVT02-GL0302 is a multicenter, randomized, double-blind, parallel-group study to evaluate PK, efficacy, safety & immunogenicity between patients receiving Humira and patients undergoing repeated switches between Humira and AVT02, followed by an optional safety Extension Phase.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Dermatology Product Name: AVT02

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Baxter Healthcare Corporation

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement March 17, 2021

            Details:

            Proceeds will be used for the development of companies lead drug AVT02. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann Family Office) from Germany invested in Alvotech.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Dermatology Product Name: AVT02

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 19, 2020

            Details:

            AVT02 is a proposed biosimilar of HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms that are expected to be beneficial to patients and to be differentiated from most biosimilar competitors, while matching the newest dosage forms of the reference product.